Symbols / BOLT Stock $5.31 +1.14% Bolt Biotherapeutics, Inc.

Healthcare • Biotechnology • United States • NCM
BOLT (Stock) Chart
O: — H: — L: — C: — V: —
SMA 20: — SMA 50: — SMA 200: —
Stock Fundamentals
Scroll to Statements
Index EQUITY
Sector Healthcare
Industry Biotechnology
CEO Mr. William P. Quinn
Exch · Country NCM · United States
Market Cap 10.20M
Enterprise Value 9.62M
Income -29.58M
Sales 6.50M
FCF (ttm) -20.98M
Book/sh 10.32
Cash/sh 11.91
Employees 23
Insider 10d —
IPO Feb 05, 2021
Div forward ($/yr)
Div TTM ($/yr)
Dividend Yield
Ex-Div Date
5Y Avg Yield
Yield vs 5Y Avg
Payout 0.00%
P/E —
Forward P/E -0.02
PEG —
P/S 1.57
P/B 0.51
P/C —
EV/EBITDA -0.33
EV/Sales 1.48
Quick Ratio 3.12
Current Ratio 3.51
Debt/Eq 112.54
LT Debt/Eq —
EPS (ttm) -16.40
EPS next Y -254.96
EPS Growth —
Revenue Growth -97.90%
EPS Gr Q/Q —
Rev Gr Q/Q —
Earnings (next) 2026-03-12
Earnings (prior) 2026-03-12
ROA -28.12%
ROE -88.79%
ROIC —
Gross Margin 0.00%
Oper. Margin -292.35%
Profit Margin 0.00%
Shs Outstand 1.92M
Shs Float 1.77M
Insider Own 7.10%
Instit Own 28.86%
Short Float 0.63%
Short Ratio 0.44
Short Interest 12.13K
52W High 7.35
vs 52W High -27.76%
52W Low 3.91
vs 52W Low 35.81%
Beta —
Impl. Vol. —
Rel Volume 0.91
Avg Volume 24.38K
Volume 22.15K
Target (mean) $41.00
Tgt Median $41.00
Tgt Low $7.00
Tgt High $75.00
# Analysts 2
Recom Buy
Prev Close $5.25
Price $5.31
Change 1.14%
About

Bolt Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel immunotherapies for the treatment of cancer. The company's pipeline products include BDC-4182, a next-generation Boltbody ISAC that targets the tumor-associated antigen claudin 18.2 for the treatment of gastric/gastroesophageal junction cancer, pancreatic cancer, and other tumor types; BDC-3042, a dectin-2 agonist antibody program for the treatment of non-small cell lung cancer, melanoma, and other solid tumors; CEA ISAC, a Boltbody ISAC targeting carcinoembryonic antigen cell adhesion molecule 5 for the treatment of solid tumors, including colorectal, non-small cell lung, pancreatic, and breast; and PD-L1 ISAC, a novel human anti-PD-L1 antibody conjugated to a next-generation TLR7/8 agonist payload via a non-cleavable linker to target both tumor and immune cells for the treatment of tumor regression and immunological memory. The company has collaboration agreements with Toray Industries, Genmab A/S, and Innovent Biologics, Inc.; and a license agreement with Stanford University. The company was formerly known as Bolt Therapeutics, Inc. and changed its name to Bolt Biotherapeutics, Inc. in July 2015. Bolt Biotherapeutics, Inc. was incorporated in 2015 and is headquartered in Redwood City, California.

Valuation Models

Price estimates from analyst targets and simple models.

1. Analyst consensus
$41.00
Mean price target
2. Current target
$5.31
Latest analyst target
3. DCF / Fair value
$-196.56
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$5.31
Low
$7.00
High
$75.00
Mean
$41.00

Latest analyst rating changes

Date Action Analyst Rating Change Price Target
2026-05-29 init Rodman & Renshaw — → Buy $22
2026-05-28 reit HC Wainwright & Co. Buy → Buy $7
2026-03-13 reit HC Wainwright & Co. Buy → Buy $7
2025-08-15 main Lake Street Buy → Buy $75
2025-05-20 init Lake Street — → Buy $4
2025-05-13 main Stifel Hold → Hold $1
2025-03-25 reit HC Wainwright & Co. Neutral → Neutral —
2025-03-25 main Stifel Hold → Hold $1
2024-11-13 reit HC Wainwright & Co. — → Neutral —
2024-08-15 reit HC Wainwright & Co. — → Neutral —
2024-05-15 down Leerink Partners Outperform → Market Perform $1
2024-05-15 down Jones Trading Buy → Hold —
2024-05-15 down HC Wainwright & Co. Buy → Neutral —
2024-05-15 down Guggenheim Buy → Neutral —
2024-05-15 down Stifel Buy → Hold $2
2024-03-22 main HC Wainwright & Co. Buy → Buy $8
2023-08-08 reit HC Wainwright & Co. Buy → Buy $8
2023-08-03 reit HC Wainwright & Co. — → Buy $8
2023-06-05 reit HC Wainwright & Co. Buy → Buy $8
2023-05-26 reit HC Wainwright & Co. — → Buy $8
News
RSS: Latest BOLT news
Insider Transactions
Filed Date Insider Relationship Transaction Shares Price Value SEC
2025-12-05 QUINN WILLIAM P Chief Executive Officer — 125 $4.61 $576
2025-12-05 NEMEC SARAH Officer — 125 $4.61 $576
2025-10-22 YONEHIRO GRANT Chief Operating Officer — 30,000 $0.00 $0
2025-10-22 QUINN WILLIAM P Chief Executive Officer — 40,000 $0.00 $0
2025-10-22 NEMEC SARAH Officer — 23,000 $0.00 $0
2025-06-06 QUINN WILLIAM P Chief Executive Officer — 125 $0.32 $40
2025-06-06 NEMEC SARAH Officer — 125 $0.32 $40
Financials
Statement View
Amounts in millions (2 decimals, no suffix) • EPS per share (2 decimals) • Trend = period evolution • YoY Growth = previous period %
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Total Revenue
7.70
+0.07%
7.69
-2.36%
7.88
+37.48%
5.73
Operating Revenue
7.70
+0.07%
7.69
-2.36%
7.88
+37.48%
5.73
Operating Expense
42.33
-44.25%
75.93
-9.69%
84.07
-12.47%
96.05
Research And Development
28.53
-50.35%
57.47
-6.62%
61.54
-15.84%
73.12
Selling General And Administration
13.79
-25.26%
18.46
-18.08%
22.53
-1.73%
22.93
General And Administrative Expense
13.79
-25.26%
18.46
-18.08%
22.53
-1.73%
22.93
Other Gand A
13.79
-25.26%
18.46
-18.08%
22.53
-1.73%
22.93
Total Expenses
42.33
-44.25%
75.93
-9.69%
84.07
-12.47%
96.05
Operating Income
-34.63
+49.25%
-68.24
+10.45%
-76.20
+15.64%
-90.32
Total Operating Income As Reported
-36.11
+50.56%
-73.05
+4.13%
-76.20
+15.64%
-90.32
EBITDA
-33.34
+49.83%
-66.45
+10.61%
-74.34
+16.14%
-88.66
Normalized EBITDA
-31.86
+48.31%
-61.64
+17.08%
-74.34
+16.14%
-88.66
Reconciled Depreciation
1.29
-27.51%
1.78
-3.94%
1.85
+11.28%
1.67
EBIT
-34.63
+49.25%
-68.24
+10.45%
-76.20
+15.64%
-90.32
Total Unusual Items
-1.48
+69.24%
-4.81
0.00
—
Total Unusual Items Excluding Goodwill
-1.48
+69.24%
-4.81
0.00
—
Special Income Charges
-1.48
+69.24%
-4.81
0.00
—
Impairment Of Capital Assets
0.00
-100.00%
1.47
0.00
—
Restructuring And Mergern Acquisition
1.48
-55.73%
3.34
0.00
—
Net Income
-33.38
+47.12%
-63.12
+8.79%
-69.20
+21.45%
-88.10
Pretax Income
-33.38
+47.12%
-63.12
+8.79%
-69.20
+21.45%
-88.10
Net Non Operating Interest Income Expense
2.50
-52.50%
5.25
-24.92%
7.00
+214.84%
2.22
Net Interest Income
2.50
-52.50%
5.25
-24.92%
7.00
+214.84%
2.22
Interest Income Non Operating
2.50
-52.50%
5.25
-24.92%
7.00
+214.84%
2.22
Interest Income
2.50
-52.50%
5.25
-24.92%
7.00
+214.84%
2.22
Other Income Expense
-1.24
-804.38%
-0.14
—
—
Other Non Operating Income Expenses
0.24
-94.84%
4.67
—
—
Gain On Sale Of Security
—
—
—
—
Tax Rate For Calcs
0.00
0.00
0.00
0.00
Tax Effect Of Unusual Items
0.00
0.00
0.00
0.00
Net Income Including Noncontrolling Interests
-33.38
+47.12%
-63.12
+8.79%
-69.20
+21.45%
-88.10
Net Income From Continuing Operation Net Minority Interest
-33.38
+47.12%
-63.12
+8.79%
-69.20
+21.45%
-88.10
Net Income From Continuing And Discontinued Operation
-33.38
+47.12%
-63.12
+8.79%
-69.20
+21.45%
-88.10
Net Income Continuous Operations
-33.38
+47.12%
-63.12
+8.79%
-69.20
+21.45%
-88.10
Normalized Income
-31.90
+45.30%
-58.31
+15.74%
-69.20
+21.45%
-88.10
Net Income Common Stockholders
-33.38
+47.12%
-63.12
+8.79%
-69.20
+21.45%
-88.10
Diluted EPS
-17.85
+45.91%
-33.00
+9.84%
-36.60
+22.46%
-47.20
Basic EPS
-17.85
+45.91%
-33.00
+9.84%
-36.60
+22.46%
-47.20
Basic Average Shares
1.87
-2.06%
1.91
+0.98%
1.89
+1.21%
1.87
Diluted Average Shares
1.87
-2.06%
1.91
+0.98%
1.89
+1.21%
1.87
Diluted NI Availto Com Stockholders
-33.38
+47.12%
-63.12
+8.79%
-69.20
+21.45%
-88.10
Line Item Trend 2023-12-31
Total Assets
159.78
Current Assets
105.71
Cash Cash Equivalents And Short Term Investments
102.19
Cash And Cash Equivalents
10.81
Other Short Term Investments
91.38
Receivables
1.53
Other Receivables
1.53
Prepaid Assets
0.91
Restricted Cash
0.00
Other Current Assets
1.09
Total Non Current Assets
54.08
Net PPE
24.08
Gross PPE
29.83
Accumulated Depreciation
-5.75
Properties
0.00
Machinery Furniture Equipment
0.39
Other Properties
29.16
Leases
0.28
Investments And Advances
26.41
Non Current Deferred Assets
—
Other Non Current Assets
3.59
Total Liabilities Net Minority Interest
47.04
Current Liabilities
20.46
Payables And Accrued Expenses
9.65
Payables
2.99
Accounts Payable
2.99
Current Accrued Expenses
6.67
Pensionand Other Post Retirement Benefit Plans Current
5.82
Current Debt And Capital Lease Obligation
2.78
Current Capital Lease Obligation
2.78
Current Deferred Liabilities
2.20
Current Deferred Revenue
2.20
Total Non Current Liabilities Net Minority Interest
26.59
Long Term Debt And Capital Lease Obligation
17.44
Long Term Capital Lease Obligation
17.44
Non Current Deferred Liabilities
9.11
Non Current Deferred Revenue
9.11
Other Non Current Liabilities
0.04
Preferred Securities Outside Stock Equity
—
Stockholders Equity
112.74
Common Stock Equity
112.74
Capital Stock
0.00
Common Stock
0.00
Preferred Stock
0.00
Share Issued
1.91
Ordinary Shares Number
1.91
Treasury Shares Number
0.00
Additional Paid In Capital
476.99
Retained Earnings
-364.29
Gains Losses Not Affecting Retained Earnings
0.04
Other Equity Adjustments
0.04
Total Equity Gross Minority Interest
112.74
Total Capitalization
112.74
Working Capital
85.25
Invested Capital
112.74
Total Debt
20.22
Capital Lease Obligations
20.22
Net Tangible Assets
112.74
Tangible Book Value
112.74
Available For Sale Securities
26.41
Investmentin Financial Assets
26.41
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Operating Cash Flow
-39.85
+34.98%
-61.29
+11.85%
-69.53
+9.12%
-76.50
Cash Flow From Continuing Operating Activities
-39.85
+34.98%
-61.29
+11.85%
-69.53
+9.12%
-76.50
Net Income From Continuing Operations
-33.38
+47.12%
-63.12
+8.79%
-69.20
+21.45%
-88.10
Depreciation Amortization Depletion
1.29
-27.51%
1.78
-3.94%
1.85
+11.28%
1.67
Depreciation And Amortization
1.29
-27.51%
1.78
-3.94%
1.85
+11.28%
1.67
Other Non Cash Items
2.53
+9.97%
2.30
-22.19%
2.95
-8.47%
3.23
Stock Based Compensation
2.78
-62.44%
7.41
-19.69%
9.22
-3.69%
9.58
Asset Impairment Charge
0.00
-100.00%
1.47
0.00
—
Operating Gains Losses
-0.29
-311.43%
-0.07
—
—
Unrealized Gain Loss On Investment Securities
—
—
—
—
Gain Loss On Sale Of PPE
-0.29
-311.43%
-0.07
0.00
0.00
Change In Working Capital
-12.12
-43.54%
-8.44
+14.44%
-9.86
-222.67%
-3.06
Change In Prepaid Assets
0.08
-97.04%
2.57
+666.30%
-0.45
+49.72%
-0.90
Change In Payables And Accrued Expense
-5.43
-11.20%
-4.88
-43.07%
-3.41
-223.30%
2.77
Change In Other Working Capital
-4.64
+0.66%
-4.67
-29.59%
-3.61
-66.79%
-2.16
Change In Other Current Liabilities
-2.12
-45.64%
-1.46
+39.15%
-2.39
+13.37%
-2.76
Investing Cash Flow
44.30
-23.05%
57.58
-18.95%
71.04
+22.77%
57.86
Cash Flow From Continuing Investing Activities
44.30
-23.05%
57.58
-18.95%
71.04
+22.77%
57.86
Net PPE Purchase And Sale
0.89
+732.71%
0.11
+151.94%
-0.21
+89.45%
-1.95
Purchase Of PPE
-0.07
-75.61%
-0.04
+80.10%
-0.21
+89.45%
-1.95
Sale Of PPE
0.96
+550.68%
0.15
0.00
—
Capital Expenditure
-0.07
-75.61%
-0.04
+80.10%
-0.21
+89.45%
-1.95
Net Investment Purchase And Sale
43.41
-24.46%
57.47
-19.33%
71.24
+19.11%
59.81
Purchase Of Investment
-29.02
+67.34%
-88.86
+46.14%
-164.99
+8.70%
-180.70
Sale Of Investment
72.43
-50.50%
146.32
-38.06%
236.23
-1.78%
240.52
Financing Cash Flow
0.02
-82.41%
0.11
-57.31%
0.25
-49.70%
0.50
Cash Flow From Continuing Financing Activities
0.02
-82.41%
0.11
-57.31%
0.25
-49.70%
0.50
Net Common Stock Issuance
0.02
-82.41%
0.11
-57.31%
0.25
-49.70%
0.50
Changes In Cash
4.47
+224.02%
-3.60
-304.13%
1.77
+109.74%
-18.14
Beginning Cash Position
8.97
-28.67%
12.57
+16.34%
10.81
-62.66%
28.95
End Cash Position
13.44
+49.84%
8.97
-28.67%
12.57
+16.34%
10.81
Free Cash Flow
-39.92
+34.91%
-61.33
+12.05%
-69.73
+11.12%
-78.46
Amortization Of Securities
-0.67
+74.38%
-2.62
+41.80%
-4.49
-2541.85%
0.18
Common Stock Issuance
0.02
-82.41%
0.11
-57.31%
0.25
-49.70%
0.50
Issuance Of Capital Stock
0.02
-82.41%
0.11
-57.31%
0.25
-49.70%
0.50
Net Preferred Stock Issuance
—
—
—
0.00
Preferred Stock Issuance
—
—
—
0.00
SEC Filings

Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.

Trades
Date User Broker Pattern Type Position Size Entry Price Trade P&L Status
Posts
Published Title Author Category